Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab beta, zoledronic acid, and IL-2 in leiomyosarcoma
NCT05080790Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2021
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Dinutuximab beta in leiomyosarcoma (LMS), sponsored by Institut für Klinische Krebsforschung. Started Nov 2021; status: completed.
02
Drugs
Dinutuximab beta
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT05080790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05080790.